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Abstract
Cadmium, a widespread toxic pollutant of occupational and environmental concern, is a known human carcinogen. The
prostate is a potential target for cadmium carcinogenesis, although the underlying mechanisms are still unclear.
Furthermore, cadmium may induce cell death by apoptosis in various cell types, and it has been hypothesized that a key
factor in cadmium-induced malignant transformation is acquisition of apoptotic resistance. We investigated the in vitro
effects produced by cadmium exposure in normal or tumor cells derived from human prostate epithelium, including RWPE-
1 and its cadmium-transformed derivative CTPE, the primary adenocarcinoma 22Rv1 and CWR-R1 cells and LNCaP, PC-3 and
DU145 metastatic cancer cell lines. Cells were treated for 24 hours with different concentrations of CdCl2 and apoptosis, cell
cycle distribution and expression of tumor suppressor proteins were analyzed. Subsequently, cellular response to cadmium
was evaluated after siRNA-mediated p53 silencing in wild type p53-expressing RWPE-1 and LNCaP cells, and after adenoviral
p53 overexpression in p53-deficient DU145 and PC-3 cell lines. The cell lines exhibited different sensitivity to cadmium, and
24-hour exposure to different CdCl2 concentrations induced dose- and cell type-dependent apoptotic response and
inhibition of cell proliferation that correlated with accumulation of functional p53 and overexpression of p21 in wild type
p53-expressing cell lines. On the other hand, p53 silencing was able to suppress cadmium-induced apoptosis. Our results
demonstrate that cadmium can induce p53-dependent apoptosis in human prostate epithelial cells and suggest p53
mutation as a possible contributing factor for the acquisition of apoptotic resistance in cadmium prostatic carcinogenesis.
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Introduction
Prostate cancer is a major cause of morbidity and mortality in
humans. With an estimated 240,890 new cases, (accounting for
29% of all expected male cancers) and 33,720 deaths (11% of total
deaths caused by cancer in men) in 2011 in the USA, it is currently
the most commonly diagnosed cancer and the second leading
cause of cancer-related deaths in American men [1]. In spite of the
continuous research advance on understanding molecular mech-
anisms and pathways involved in prostate cancer growth and
progression, particularly regarding the role of androgen signaling
[2], we are still far from clearly defining the complex etiology of
this disease, which probably includes genetic background, age and
physiologic status, lifestyle (e.g. diet and tobacco smoking) and
exposure to other environmental risk factors.
In the vast group of environmental pollutants, the toxic heavy
metal cadmium is considered a likely candidate as a causative
agent for prostate cancer. Widely distributed and used in industry,
and with a broad range of target organs and a long half-life (10–30
years) in the human body, this element has been long known for its
multiple adverse effects on human health, through occupational or
environmental exposure [3]. Moreover, cadmium and cadmium
compounds have been classified by the International Agency for
Research on Cancer and the U. S. National Toxicology Program
as Group 1 human carcinogens, mainly on the basis of
epidemiological studies showing a dose-response relationship
between the level of cadmium exposure and the incidence of lung
cancer in the human population [4,5], while different experimen-
tal animal studies have clearly demonstrated that this metal can
induce tumor formation at multiple tissue sites in various species
[3]. The role of cadmium as a prostate carcinogen has been
suggested by epidemiological data and results of several animal
and in vitro studies. Some evidence exists that environmental
cadmium exposure might be associated with prostate cancer in
humans [5,6]. And several studies demonstrated that cadmium
induces tumors (adenocarcinomas) and preneoplastic (hyperplas-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33647tic) lesions of the prostate in rats [4,5,7–10]. On the other hand,
some authors reported evidence of in vitro malignant transforma-
tion of cultured prostate epithelial cells by cadmium, both with
murine [11] and human cells [12,13].
Nevertheless, the specific molecular events associated with
cadmium-induced transformation are still elusive. Actually,
considering the multiple molecular targets that have been
identified, this metal probably operates with a complex oncoge-
netic mechanism, in which more than a single pathway could be
implicated [14]. Cadmium can affect cell proliferation and
differentiation, cell cycle progression, DNA synthesis and repair,
apoptosis and other cellular activities [15,16]. On the basis of
currently available data, cadmium seems to have little direct
genotoxic activity at doses relevant for potential cell transforma-
tion [6]. However, apparently it can inhibit DNA repair [17,18],
and thus represent a cause of genomic instability, a condition that
has been associated with tumorigenesis, and even act as a co-
genotoxic chemical [19]. Different other possible indirect
mechanisms have also been proposed to explain cadmium
carcinogenesis, including oxidative stress, proto-oncogene activa-
tion, altered DNA methylation and dysregulated gene expression
[14–16]. In addition, a critical role has been proposed for
acquisition of cellular apoptotic resistance following exposure to
cadmium. As a fundamental defense mechanism against the
uncontrolled proliferation of mutated or transformed cells in the
body, apoptosis that is frequently observed in cadmium-exposed
cells would be expected to have an anti-carcinogenic function. But
in this context cadmium-induced apoptotic cell death might result
not completely protective against malignant transformation, as
suggested by some studies showing that only a fraction of exposed
cells in a population die by apoptosis, while the rest may become
apoptosis-resistant [19,20]. Furthermore, it has been shown that
cadmium-transformed or -adapted cells are characterized by
increased resistance to apoptosis [21,22], which may render them
more prone to accumulation of mutations and neoplastic
transformation. Indeed, disruption of apoptosis is considered
critical in tumor formation and malignant progression, and
acquired resistance to apoptosis is a general hallmark of cancer
[23]. Therefore, an accurate characterization of the cellular and
molecular response of prostate cells to cadmium cytotoxic action,
particularly in terms of apoptosis induction, would be of the
greatest interest. On account of this, and with the aim of giving
further experimental contribution to this matter, we carried out an
investigation on the effects of cadmium exposure on apoptosis and
the expression of some tumor suppressor proteins in cultured cells
derived from human prostate epithelium. In particular, the normal
RWPE-1 cell line was tested and confronted with the response of
its cadmium-transformed derivative CTPE. Subsequently, differ-
ent prostate cancer cell lines were analyzed, including primary
adenocarcinoma (22Rv1 and CWR-R1) and metastatic adeno-
carcinoma cells (LNCaP, PC-3 and DU145).
Materials and Methods
Cell lines, culture conditions and treatment with
cadmium
Seven different human prostate epithelial cell lines were used
(Table 1). RWPE-1 is a HPV18 immortalized, non-tumorigenic
prostatic cell line which was established in 1997 from a
histologically normal prostate [24]. On the other hand, the
cadmium-transformed CTPE cell line was derived from RWPE-1
cells that acquired features of malignant nature after chronic
exposure to 10 mM cadmium chloride [12]. 22Rv1 and CWR-R1
are related cell lines, both derived from a subline (CWR22R-2152)
established from a xenograft of the primary tumor CWR22R [25].
LNCaP, DU145 and PC-3 are classical metastatic prostate
adenocarcinoma cell lines, derived, respectively, from lymph
node, brain and bone metastasis. All cell lines were maintained at
37uC in a humidified atmosphere containing 5% CO2 and passed
weekly. RWPE-1 and CTPE cells were grown in Keratinocyte
Serum-Free Medium (K-SFM) containing 50 mg/ml bovine
pituitary extract (BPE), 5 ng/ml human (recombinant) epidermal
growth factor (EGF) and 1% penicillin/streptomycin antibiotic
solution. The other cell lines (22Rv1, CWR-R1, LNCaP, DU145
and PC-3) were grown in RPMI 1640 medium supplemented with
10% FBS. K-SFM and supplements (BPE and EGF) were
purchased from Gibco, USA, while RPMI 1640 and FBS were
obtained from Invitrogen Life Technologies, USA.
For short-term treatment with cadmium, cells were maintained
in culture medium containing cadmium chloride, at a desired
concentration, for 24 h.
Flow cytometric analysis of cell cycle distribution
To evaluate the percentages of cells at the various stages of the
cell cycle, flow cytometric analysis of nuclear DNA content was
performed. Following treatment, cells were harvested with trypsin,
washed with PBS, fixed in cold (220uC) 70% ethanol (about 10
6
cells in 10 ml) and then stored in 70% ethanol at +4uC.
Table 1. Origin of the human prostate epithelial cell lines included in this study and mutation analysis of their p53 locus.
Cell line Origin Ref. p53 Exon Nucleotide change Codon change Ref.
RWPE-1 Normal prostate
a [24] Wild type [24]
CTPE RWPE-1 cells
b [12] Wild type [12]
22Rv1 Primary tumor xenograft
c [29] 9 CAGRCGG Q331R [25]
CWR-R1 Primary tumor xenograft
c [25,30] 8/9 CGTRCAT/CAGRCGG A273H/Q331R [25]
LNCaP Lymphnode metastasis [28] Wild type [34,35]
DU 145
d Brain metastasis [31,32] 6/8 CCTRCTT/GTTRTTT P223L/V274F [34,35]
PC3 Bone metastasis [33] 5 GCCRGC (del. C) 138, frameshift, STOP codon
169
[34,35]
aHPV18 immortalized cells.
bTransformed by chronic CdCl2 exposure.
cSubline CWR22R-2152.
dBoth alleles mutated, mutations in exons 6 and 8 in different alleles [53].
doi:10.1371/journal.pone.0033647.t001
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PBS, resuspended in DNA staining solution (20 mg/ml propidium
iodide and 25 mg/ml RNase A (Sigma) in PBS), and incubated at
37uC for 30 min. Subsequently, cell cycle distribution (DNA
histograms) was analyzed by using a BD FACS Aria flow
cytometer and the BD FACS Diva software (v5.0.1). Cell doublets
and cell aggregates were not gated during analyses.
Flow cytometric detemination of apoptosis
Apoptotic cell death in prostate cell line cultures was
determined using an Annexin-V FITC Apoptosis Detection kit
(Bender MedSystems, GmbH, Vienna, Austria) according to the
manufacturer’s instructions. Briefly, cells were harvested, washed
with PBS and resuspended in Annexin-V binding buffer. Then,
the cells were stained with FITC-conjugated Annexin-V (1:40
diluted stock solution in binding buffer) for 10 min at room
temperature in the dark. After washing with binding buffer and
staining with propidium iodide (1 mg/ml), cells were finally
analyzed on a BD FACS Aria flow cytometer using BD FACS
Diva software (v5.0.1). Early apoptotic cells were identified as
Annexin V-positive/propidium iodide-negative cells.
p53-specific siRNA transfection
For p53 silencing, RWPE-1 and LNCaP cells were seeded in 6-
well plates at a density of 1610
5 cells per well, grown up to 40–
50% confluence and then transfected with p53-specific siRNA
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), according to
manufacturer’s protocols. Briefly, 8 ml of p53 siRNA stock solution
(10 mM) and 6 ml of transfection reagent (Santa Cruz Biotechnol-
ogy Inc.) were separately diluted in 100 ml transfection medium
(Santa Cruz Biotechnology Inc.) each, and incubated for 30 min at
room temperature; then they were mixed together and further
diluted with transfection medium up to a final volume of 1 ml
(final concentration of p53 siRNA=40 nM). After washing with
transfection medium, cells were incubated with the mixture for
6 hours (100 ml per well), then an equal volume of culture medium
with double concentrated-supplements was added and the cells
incubated for additional 18 hours. At 24 hour post-transfection
the transfection mixture was replaced with fresh complete medium
and the cells were cultured for 24 hours before experiments of
cadmium chloride exposure. For both RWPE-1 and LNCaP cell
lines a FITC-conjugated unspecific siRNA (Santa Cruz Biotech-
nology Inc.) was used as a control for siRNA experiments, and
optimal conditions for transfection (siRNA and transfection
reagent concentrations, incubation times) were determined in
preliminary experiments by using fluorescence microscopy eval-
uation of the transfection efficiency.
Adenovirus infection (Adp53-mediated gene transfer)
A recombinant E1-deleted replication-defective adenoviral
vector encoding human wild type p53 (Adp53), with the p53 gene
under the control of the human cytomegalovirus enhancer/
promoter, was generated using the AdEasy system (Carlsbad, CA).
Viral stock was prepared from a single clone of the Adp53 virus,
obtained by plaque purification and amplified in the HEK 293 cell
line (ATCC CRL-1573), carrying, and stably expressing, the E1
gene required for adenoviral replication.
For transduction of wild-type p53-deficient prostate cell lines,
DU145 and PC-3 cells were seeded in 10 cm plates and cultured
up to 40–50% confluence. Viral stock was diluted in RPMI 1640
supplemented with 2% heat-inactivated FBS and added directly to
monolayer cultures. To avoid cytotoxic effects on target cells,
preliminary tests were performed by using increasing MOI
(Multiplicity Of Infection) of Adp53 for each cell line. Subse-
quently, cells were infected with 50 MOI of Adp53. After 8 h
incubation, medium was replaced with complete 10% FBS RPMI
1640 and cells were grown for additional 16–24 hours before
starting treatment with CdCl2.
Western blot analysis
After the indicated treatments, cells were harvested and washed
twice with cold PBS, and the resulting dry cell pellets were
immediately stored at 280uC. For total cellular protein extraction,
cells were lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4,
250 mM NaCl, 50 mM NaF, 5 mM EDTA, 0.1% Triton X-100,
0.1 mM Na3VO4) containing protease inhibitors (Complete, Mini,
EDTA-free from Roche), for 30 min at 4uC. The lysates were
cleared by centrifugation at 14,000 g for 10 min at 4uC and the
supernatants were either used immediately or stored at 280uC
until use. Protein concentrations were determined by using the
ND-1000 Spectrophotometer (Agilent Technologies). For immu-
noblot analysis, equal amounts of protein (30–50 mg) were mixed
with loading buffer and boiled for 5 min. The samples were then
loaded and resolved on 7–12% SDS-polyacrylamide gels. After
electrophoresis, the proteins were electrotransferred to nitrocellu-
lose membranes. The blots containing the transferred proteins
were blocked with 5% non-fat dry milk in TBS-T (20 mM Tris-
HCl, pH 7.6, 137 mM NaCl, 0.5% Tween 20), for 1 hour at
room temperature or overnight at 4uC, and then incubated with
primary antibodies in TBS-T containing 3% non-fat dry milk for
2 hours at room temperature or overnight at 4uC. The following
primary antibodies were used: mouse monoclonal antibodies
against p53 (1:500), p21 (1:500), b-actin (1:5,000), and nucleolin
C-23 (1:1,000) (Santa Cruz Biotechnology, Santa Cruz, CA);
rabbit polyclonal antibodies against p27 (1:500), p16 (1:250), pRb/
p105 (1:1,000), p107 (1:250), and pRb2/p130 (1:250) (Santa Cruz
Biotechnology, Santa Cruz, CA); and a mouse monoclonal
antibody against Glyceraldehyde-3-phosphate dehydrogenase/
GAPDH (1:1,000) (Chemicon, Billerica, MA). After washing,
membranes were finally incubated with appropriate, species-
specific horseradish peroxidase-conjugated secondary antibodies,
used at 1:10,000 or 1:20,000 dilution in TBS-T for 1 hour at room
temperature. Immunocomplexes were detected with the enhanced
chemiluminescence system (ECL, Amersham, CA) and by
autoradiography using X-ray film (FUJI Photo Film Co, Inc.,
Tokyo, Japan). Protein expression levels were determined semi-
quantitatively by densitometric analysis with the Quantity One
software (BioRad) using scanned autoradiographic images.
Statistical analysis
Data/results are presented as means 6 SD or SEM, calculated
from at least three replicate determinations of the endpoints
examined. The significance of the differences between treatments
and respective controls was determined by Student’s t test. P,0.05
was considered statistically significant (* P,0.05; ** P,0.01;
*** P,0.001).
Results
Apoptosis induction by cadmium in RWPE-1 and CTPE
cells
To evaluate the ability of cadmium to trigger apoptotic cell
death in prostate epithelial cells at concentrations comparable with
observed in vivo levels in exposed humans, the cells were treated for
24 hours with different concentrations of cadmium chloride, in the
range 0–30 mM, and early apoptosis was detected and quantified
by means of FACS analysis after staining with FITC-conjugated
Annexin-V and propidium iodide, while parallel FACS analysis of
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Cadmium exposure was clearly responsible for the induction of
apoptosis in RWPE-1 normal prostate cells (Fig. 1B), as evidenced
by a dose-dependent increase in the frequency of early apoptotic
cells (Annexin V-positive/propidium iodide-negative). This effect
was already obtained at 10 mM cadmium chloride (about 3.5-fold
increase, p,0.01), and could be easily observed under the inverted
microscope, with apoptotic cells exhibiting cytoplasmic shrinkage
and/or blebbing, and detaching from each other or floating in the
medium (Fig. 1A). By FACS analysis of cell DNA content, a
remarkable increase in sub-G1 fraction was also seen (Fig. 1D).
Since sub-G1 peaks include early and late apoptotic cells, but also
a part of necrotic cells, such large sub-G1 fractions provide strong
evidence for cadmium cytotoxicity resulting in a global reduction
in the number of viable cells, which is also reflected in decreased
S+G2/M fractions. CTPE cells (cadmium-transformed derivatives
of RWPE-1) resulted more resistant to apoptosis induction, which
was observed only at concentrations=20 mM (about 2.5-fold
increase, p,0.05; Fig. 1A9,B9). Moreover, clear effects on cell
cycle distribution, with some increase in sub-G1 fraction, were
obtained only at the highest concentration employed (30 mM;
Fig. 1D9).
Western blot analysis of p53, p21 and p27 tumor
suppressor protein expression in RWPE-1 and CTPE cells
To shed light onto the molecular mechanisms underlying the
response of prostate epithelial cells to cadmium cytotoxic activity,
and to assess the possible involvement of tumor suppressor
proteins that are frequently altered or deregulated in most types of
cancer, western blot analysis was used to detect the levels of total
p53, p21 and p27 proteins in RWPE-1 and CTPE cells (Fig. 1C,
C9). Cadmium treatment resulted in significant concentration-
dependent elevations of total p53 in RWPE-1 and, to a lesser
extent, CTPE cells. A parallel dose-dependent increase was also
observed in the levels of p21, a protein that is produced by a target
gene of p53. As for p27, no significant variations in the levels of
this protein were observed after 24-hour cadmium treatment in
both cell lines, apart from a modest, 1.5-fold increment at 20 mM
cadmium chloride in RWPE-1.
Parallel immunoblot analysis of p16 and the three members of
the pRb protein family (pRb, pRb2/p130 and p107) were also
performed; no change in the phosphorylation status of these
proteins was recorded and only minor variations were detected in
their levels, while no clear trend in response to increasing
concentrations of the metal could be evidenced (data not shown).
Effects of cadmium on prostate cancer cell lines
The primary carcinoma 22Rv1 and the metastatic LNCaP cell
lines responded in a similar way to 24-hour cadmium treatment,
both exhibiting, in a dose-dependent manner and starting from
10 mM cadmium chloride, apoptosis induction (Fig. 2A, B and A9,
B9), increase in the proportion of sub-G1 cells and reduction in
S+G2/M fraction, as well as decreased G1 fraction (Fig. 2D, D9),
clearly visible in 22Rv1 cells only at 30 mM. On the other hand,
the other primary carcinoma cell line, CWR-R1, did not display
any significant effects at cadmium doses lower than 30 mM: only at
this concentration a significant increase in apoptosis and in subG1
cells could be found, together with a decrease in S+G2/M cell
fraction (not shown). Differently from all these cell lines, the
metastatic prostate cancer PC-3 and DU145 cells were not
affected by cadmium toxic activity in the range of concentrations
employed (Fig. 3A, B, D and A9,B 9 and D9).
As regards the expression of tumor suppressor proteins, only
LNCaP cells exhibited a significant concentration-dependent
increase in total p53 after cadmium exposure (Fig. 2C9). A
relatively small, 1.6-fold increase could also be detected in 22Rv1
cells at 30 mM cadmium (p,0.05; Fig. 2C). Conversely, no
variations in p53 levels were observed in CWR-R1 (not shown)
and DU145 (Fig. 3C9) cell lines, displaying high basal protein
expression, whereas PC-3 cells did not express detectable amounts
of p53 protein (Fig. 3C). Accordingly, the levels of p21 followed a
similar pattern of expression, with a 1.4-fold increment in 22Rv1
at 30 mM cadmium (p,0.05; Fig. 2C), while they remained
essentially unchanged in CWR-R1 (not shown), and PC-3 and
DU145 cell lines (Fig. 3C, C9). On the contrary, and unexpectedly,
in LNCaP cells p21 levels seemed to decrease with increasing
cadmium chloride concentrations (Fig. 2C9). Regarding p27 levels,
no significant variations were observed after 24-hour cadmium
treatment in PC-3 (Fig. 3C) and CWR-R1 (not shown) cells, at any
of the tested cadmium concentrations. On the other hand, 22Rv1,
LNCaP and DU145 cell lines displayed slightly increased (about
1.5-fold) levels of p27 only at the highest concentration employed
(30 mM; Fig. 2C, C9 and Fig. 3C9).
Effects of siRNA-induced silencing of p53 protein in
prostate epithelial cells
Since western blot analysis clearly revealed that cadmium
apoptosis induction is correlated with elevations in p53 levels, at
least in cell lines expressing wild-type p53, silencing of p53 by
means of specific small interfering RNA was attempted in order to
verify the role played by this oncosuppressor in the response of
RWPE-1 (normal) and LNCaP (metastatic) cells to cadmium
exposure. After determining optimal experimental conditions for
obtaining efficient transfection, RWPE-1 and LNCaP cells, both
possessing normal, wild type p53 genes, were transfected with p53-
siRNA and, 2 days later, treated with 20 mM cadmium chloride.
Then, apoptosis detection and western blot analysis were
performed. Results of western blotting analysis (Fig. 4A) proved
that effective silencing of p53 was obtained in both cell lines. This
effect was particularly evident in p53-siRNA transfected cells that
were treated with 20 mM cadmium chloride, since in these cells
only a slight, non statistically significant increase in p53 levels was
obtained, as compared to control cadmium-exposed cells, in which
p53 levels were 6-fold (RWPE-1) or 2.4-fold (LNCaP) higher than
in their respective untreated controls. Moreover, p21 levels
changed in accordance with p53 variations in RWPE-1 cells. In
LNCaP cell line, on the other hand, the protein levels of p21 were
decreased after incubation with 20 mM cadmium chloride, both in
control and in p53-siRNA transfected cells (p,0.05). This
observation confirmed our previous results (Figure 2D9), and was
a further indication that p21 regulation in LNCaP might be, at
least in part, independent of p53. Conversely, no significant
changes were found in the levels of p27 protein in LNCaP cells, as
observed at the same concentration in previous experiments. In
RWPE-1 cells, on the contrary, p27 levels were enhanced in both
control and p53-siRNA transfected cells, after treatment with
20 mM cadmium chloride. In correlation with the effective p53
silencing no significant induction of apoptotic cell death was
observed in p53-siRNA transfected cells after 24-hour exposure to
20 mM cadmium chloride, as compared to the relative control.
This was clearly evident in LNCaP cells (Fig. 4B,C). In the case of
RWPE-1, unfortunately p53-siRNA transfection caused a small
increase in the basal level of early apoptosis, which is indicative of
a certain sensitivity of these cells to the possible toxic consequences
of p53-siRNA treatment per se (data not shown).
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33647Figure 1. Cadmium induces dose-dependent apoptosis and p53 overexpression in RWPE-1 and CTPE human prostate cells.
Cadmium effects on RWPE-1 (A–D) and CTPE (A9–D9) cells, after 24-h treatment with different concentrations of CdCl2 (0, 10, 20 and 30 mM). A, A9:
representative phase contrast microscopy images. B, B9: early apoptosis detection by FITC-conjugated Annexin-V/PI and FACS analysis. C, C9: western
blot analysis of p53, p21 and p27 expression. D, D9: FACS analysis of cell DNA content. Histograms in B, B9 report mean percentages 6 SEM of
Annexin-V positive/PI-negative cells (n=3). Histograms in C, C9 represent relative band densities (mean 6 SEM, n=3), as determined by densitometry,
using b-actin as the loading control for standardization. Scale bars in A, A9=100 mm. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0033647.g001
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33647Figure 2. Cadmium induces dose-dependent apoptosis in LNCaP and 22Rv1 prostate cancer cell lines. Cadmium effects on LNCaP (A–D)
and 22Rv1 (A9–D9) cells, after 24-h treatment with different concentrations of CdCl2 (0, 10, 20 and 30 mM). Same conditions as in figure 1. A clear
correlation between apoptosis induction and p53 overexpression is particularly evident in wt p53-expressing LNCaP cells. Scale bars in A,
A9=100 mm. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0033647.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33647Figure 3. Cadmium does not induce apoptosis in p53-deficient PC3 and DU145 prostate cancer cell lines. Cadmium effects on PC3 (A–
D) and DU145 (A9–D9) cells, after 24-h treatment with different concentrations of CdCl2 (0, 10, 20 and 30 mM). Same conditions as in figure 1. Scale
bars in A, A9: 100 mm. * P,0.05.
doi:10.1371/journal.pone.0033647.g003
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deficient prostate cancer cell lines
To further verify whether prostate epithelial cell sensitivity to
cadmium is dependent on p53, the effects of restoration of wild
type p53 expression in p53-defective DU145 and PC-3 cell lines
were investigated. PC-3 are p53-null, while DU145 cells carry two
mutations (codons 223 and 274) in the p53 gene (Table 1) and
express a non-functional mutant form of the protein, which tends
to accumulate intracellularly. Overexpression of wt p53 was
obtained by means of transduction with a recombinant Adp53
adenoviral vector. Subsequently, transduced cells were treated for
24 hours with different concentrations of cadmium chloride (in the
range 0–30 mM) and were tested for apoptosis induction, cell cycle
distribution and expression of p53 and p21 tumor suppressor
proteins.
In the case of PC-3, western blot analysis (Fig. 5B) demonstrated
the successful expression of high levels of wt p53 protein in these
p53-null cells, with the concomitant highly enhanced (about 7-
fold) expression of the p53 target gene p21, as compared to non-
transduced cells. The levels of the p21 protein remained, however,
unchanged after cadmium chloride treatment. In accordance with
the increased expression of p21, cell cycle distribution was, to a
certain extent, altered in comparison with non-transfected cells: in
particular, a higher proportion of cells in the G2/M fraction was
found, together with reduced percentages of cells in the G1 and S
phases and a minor increase in the sub-G1 fraction (Fig. 5C). But,
again, 24-hour exposure to cadmium chloride was unable to
induce any significant changes in the relative proportions of the
different cell cycle fractions. As regards apoptosis detection, no
significant differences were seen between Adp53-transfected and
non-transfected cells, and no variations occurred following
cadmium chloride treatment (Fig. 5A). Partly similar results were
obtained with DU145 cells. Adp53 transfection caused wt p53
overexpression and a parallel elevation (about 5-fold) in the
expression levels of p21 (Fig. 6B). As in PC-3, p21 levels were
substantially unaffected by cadmium chloride treatment. More-
over, Adp53 overexpression caused a change in the cell cycle
distribution, but different from what observed in PC-3 cells: the
main effects in DU145 cells were a marked reduction in the
proportion of cells in the S+G2/M fraction and a striking increase
Figure 4. Silencing of p53 suppresses apoptosis induction by cadmium in human prostate cells. p53 siRNA transfection: western blot
analysis (RWPE-1 and LNCaP cells) and early apoptosis detection (LNCaP cells). WB analysis of p53, p21 and p27 expression (A), representative phase
contrast microscopy images (B) and FITC-conjugated Annexin-V/PI and FACS analysis (C; histograms, reporting mean percentages 6 SEM of Annexin-
V positive/PI-negative cells, n=3) after p53 siRNA transfection, followed by 24-h treatment with 20 mM CdCl2. In LNCaP cells siRNA-mediated p53
silencing is able to suppress apoptosis induction by 24-hour exposure to 20 mM cadmium chloride, as compared to the respective control. WB
histograms represent relative band densities (mean 6 SEM, n=3), as determined by densitometry, using b-actin as the loading control for
standardization. Scale bar in B: 100 mm. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0033647.g004
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cadmium treatment did not seem to cause any variations in the cell
cycle with respect to the control. The only, minimal effect
obtained after Adp53 overexpression in DU145 cells was a slightly
increased susceptibility to the induction of apoptosis by cadmium
chloride, which was significantly different from control cells
(p,0.05) at 20 and 30 mM concentrations (Fig. 6A), although the
detected levels of early apoptotic cells were anyhow very low.
Discussion
An established lung carcinogen in humans [4], the heavy metal
cadmium is also suspected of playing a role in the induction and the
development of prostate cancer in exposed subjects. A relation
betweencadmium exposureand prostate canceretiologyseemsto be
supported by laboratory and epidemiologic studies [3], but the
specific molecular events associated with cadmium-induced trans-
formation are still elusive. As reported above, different possible
mechanismsmaybeinvolvedincadmiumcarcinogenesis.Akeyrole,
in particular, has been proposed for apoptosis induction and the
possible subsequent acquisition of apoptotic resistance, as already
observed during malignant transformation of cadmium-exposed and
-adaptedcells[21,22].Ourinvestigationwasaimed at characterizing
the cadmium-induced apoptotic response in normal and tumor cells
derived from human prostate epithelium at doses relevant to human
exposure. In this regard, we used cadmium concentrations (10–
30 mM) that are within the range that have been found in normal,
hypertrophic and malignant human prostate tissues [26] and that, at
Figure 5. Effects of wt p53 overexpression and cadmium treatment in PC-3 cells. A: early apoptosis detection. The frequencies of apoptotic
cells were determined in both Adp53-transduced and control PC-3 cells by FITC-conjugated Annexin-V/PI and FACS analysis after 24-h treatment with
different CdCl2 concentrations (0,10, 20 and 30 mM). Histograms represent mean percentages 6 SEM of Annexin-V positive/PI-negative cells (n=3). B:
western blot analysis. The levels of total p53 and p21 proteins were examined after Adp53-mediated overexpression of wild type p53, followed by 24-
h treatment with different CdCl2 concentrations (0,10,20 and 30 mM). Histograms represent relative band densities (mean 6 SEM, n=3), as
determined by densitometry, using b-actin as the loading control for standardization. C: cell cycle distribution. FACS analysis of Adp53-transduced
and control PC-3 cells was performed after 24-h treatment with different CdCl2 concentrations (0, 10, 20 and 30 mM).
doi:10.1371/journal.pone.0033647.g005
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[27]. Higher cadmium concentrations are more prone to cause
necrosis [27] and were thus beyond the scope of our study.
As expected, normal and cancer prostate cells have exhibited
rather dissimilar response after 24-hour cadmium treatment. If we
consider both apoptosis induction and inhibition of cell prolifer-
ation the normal RWPE-1 cell line resulted, on the whole and with
the exception of LNCaP cells, the most sensitive to cadmium
cytotoxicity. On the other hand, its cadmium-transformed
derivative CTPE, proved to be more resistant to the metal
toxicity. Differences in results have been even conspicuous among
prostate cancer cells of different origin. LNCaP cells (derived from
a lymph node metastasis, androgen-responsive and relatively
androgen-dependent, see [28]) exhibited a very high sensitivity to
cadmium cytotoxic action. Of the remaining cell lines, the primary
carcinoma-derived 22Rv1 and CWR-R1, resulted more sensitive
than the two metastatic cell lines, DU145 and PC-3. These latter
were not significantly affected by cadmium treatment in the range
of concentrations employed.
Interestingly, cadmium sensitivity and apoptosis induction in
prostate cells clearly correlated to the expression of functional,
wild-type p53 protein. In fact, like the normal RWPE-1 cell line,
also LNCaP cells, that resulted the most cadmium-sensitive
prostate cancer cell line in our experiments, express wt p53.
Conversely, all the other prostate cancer lines (22Rv1, CWR-R1,
DU145 and PC-3) have mutated versions of the protein (Table 1,
[29–35]). CTPE cells express wt p53 as well, but they are
intrinsically more resistant to cadmium as a result of a specific
selection procedure [12]; these cadmium-transformed cells, for
instance, display a Bcl-2/Bax ratio about 5 times higher than in
the parental RWPE-1 cell line, which confers them a higher
resistance to apoptosis induction [21]. Western blot analysis
confirmed this correlation between wt p53 expression and
cadmium-induced apoptosis in prostate cells, revealing a strong,
concentration-dependent increase in p53 levels in both RWPE-1
and LNCaP cells exposed to cadmium, parallel to the dose-
dependent increase in apoptotic cell death. A similar, but less
evident effect was observed also in CTPE cells, while a slight
Figure 6. Effects of wt p53 overexpression and cadmium treatment in DU145 cells. Early apoptosis detection (A), western blot analysis of
p53 and p21 proteins (B) and cell cycle distribution (C) in Adp53-transduced and control DU145 cells after 24-h treatment with different CdCl2
concentrations (0, 10, 20 and 30 mM). Same conditions as in figure 5.
doi:10.1371/journal.pone.0033647.g006
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p53-mutated 22Rv1 cells. This could be explained by the
observation that 22Rv1 cells, although carrying a mutated p53
allele, might retain the ability to synthesize a small quantity of
functional p53 protein, since they still contain a wt p53 allele [25].
Indeed, a major role in cadmium-induced apoptosis has already
been suggested for the p53 tumor suppressor protein. Increased
levels of p53 protein and mRNA have been observed in different
cell lines undergoing apoptotic cell death after cadmium
treatment, including primary epithelial lung cells [36], skin
epidermal cells [37] and embryonic fibroblasts [38]. In agreement
with our results, Achanzar et al. reported increased expression of
p53, together with c-myc and c-jun, in the same normal prostate
cell line (RWPE-1) that has been used here, after exposure to
10 mM cadmium chloride [20]. In particular, they found
transiently increased levels of p53 mRNA, as a prelude to
subsequent massive apoptosis induction. Similar results (increased
p53 mRNA levels and consequent apoptosis) were also obtained by
Zhou et al. in the ventral prostate of rats, after a single
subcutaneous injection of cadmium chloride solution [39].
In addition, our analysis of p21 expression in cadmium-treated
cells has indirectly confirmed the observed variations in p53 levels.
A member of the Kip/Cip-family of CDK-inhibitors, p21 (also
known as p21
Cip1/Waf1) is a p53-downstream gene that mediates
p53-induced growth arrest in G1, mainly by suppressing the
activity of the cyclin A, E/CDK2 complex, necessary for G1/S
transition [40]. As the product of a target gene of p53, p21 levels
may serve as an indirect indicator of the activation state of p53 in
the cell. Looking at our results, it is evident that p21 levels follow a
pattern of expression largely comparable to that of p53, in the
normal RWPE-1 cell line, as well as in CTPE and 22Rv1 cells,
indicating that the observed, dose-dependent increases in the levels
of p53 after cadmium exposure are really corresponding to its
activation, as a response to toxic stress. On the other hand,
intriguingly, p21 protein levels tend to decrease while p53 is
increasing in LNCaP cells; an apparently paradoxical phenome-
non that has been, however, already observed by Tang et al. who
reported, in LNCaP cells, time-dependent increase in p53 levels
upon growth factor withdrawal, with consequent apoptosis
induction, and concomitant gradual decrease in the levels of p21
[41]. In this regard, the authors concluded that: (a) p21 expression
may be unrelated to or independent of p53 status, as suggested by
other data; and (b) p53 and p21 may be involved in prostate cell
apoptosis independently of each other, as observed in oncogene-
mediated fibroblast apoptosis.
A further confirmation of the key role played by p53 in prostate
cell apoptosis has come from the results of our experiments of
siRNA-induced silencing, at least in LNCaP cells, in which the
knockdown of p53 protein levels by p53siRNA transfection has
been sufficient to reduce the sensitivity to 20 mM cadmium
chloride, an otherwise highly toxic dose to these cells.
What signaling pathways are involved in p53 activation
following cadmium exposure of prostate epithelial cells? Consid-
ering its role of ‘‘guardian of the genome’’, acting as a key
checkpoint of cellular behaviour in response to DNA damage [42],
one could expect p53 to be activated by cadmium-induced
genotoxic stress, through ATM/ATR protein kinases-mediated
uncoupling of p53 from its main negative regulators MDM2 and
MDM4, leading to accumulation of stable active p53 protein [43].
In reality, as already mentioned, cadmium has very little, if any,
direct genotoxic activity at doses comparable with those used in
the present study [6], even if it seems to be able to inhibit DNA
repair and act as a co-genotoxic agent [17–19]. Moreover,
preliminary experiments we performed to assess cadmium
genotoxicity on prostate cells by means of cytokinesis-block
micronucleus assay, failed to reveal any significant genotoxic
effects (Text S1 and Table S1). If confirmed, these last results
would indicate that some other type of cellular stress is responsible
for p53 activation in cadmium-exposed prostate cells. Particularly
interesting in this regard seems to be the role played by oncogenic
signaling, because one of the reported effects of cadmium,
obtained in different cell types, is the activation of proto-
oncogenes, including c-fos, c-myc and c-jun, [15,16,44,45]. This
effect has been described also in the normal prostate RWPE-1 cell
line, in which induction of c-myc and c-jun concomitant with p53
up-regulation was observed after treatment with 10 mM cadmium
chloride [20]. Therefore, it is not unlikely that cadmium-induced
p53 up-regulation in prostate cells may be largely due to proto-
oncogene activation, leading to ARF induction, with the
consequent inhibition of MDM2 independently of the DNA
damage pathway [43]. The possibility of an alternative explana-
tion, however, is suggested by some recently published results. In
particular, it has been found that cadmium exposure of rat renal
tubular cells can cause down-regulation of ubiquitin conjugating
enzymes of the Ube2d family with increased levels of p53.
Considering that some Ube2d family members seem to be
involved in p53 ubiquitination and degradation, these results
would indicate that cadmium-induced p53 accumulation could
also be due to inhibition of its degradation through suppression of
Ube2d gene expression [46].
In apparent contrast with these data, our results of wt p53
overexpression in p53-deficient DU145 and PC-3 cell lines would
not seem to support a role for this protein in cadmium-induced
apoptosis. Despite high levels of wt p53 were expressed in both cell
lines after Adp53 transduction, with concomitant net increase in
p21 levels and reduced proliferation, no effects on apoptosis
susceptibility after cadmium exposure were seen in PC-3 cells, and
only minimal effects were found in DU 145 cells. In these
metastatic cancer lines, p53 functional restoration seems insuffi-
cient to enhance the sensitivity to this toxic metal, but this does not
necessarily rule out a crucial function of p53 in triggering apoptosis
by cadmium. Instead, it may simply indicate that other factors,
besides lack of functional p53, may be responsible for PC-3 and
DU145 resistance to cadmium-induced apoptosis. One such factor
may be represented by metallothioneins (MT), metal-binding
proteins whose basal or induced levels may influence the
susceptibility to cadmium toxic effects, including apoptosis [47].
Yet, induction of MT-I by cadmium was reported in the
cadmium-sensitive LNCaP cell line, while, on the contrary, the
MT-I promoter was found suppressed in the cadmium-resistant
DU145 and PC-3 cells [48], which suggests that MTs should not
be determinant for the observed differences in the response of our
prostate cell lines. An alternative explanation might be in the
different expression of other regulators of the apoptotic pathway(s),
and particularly the antiapoptotic proteins called IAPs (Inhibitors
of Apoptosis Proteins); in fact, McEleny et al. reported that PC-3
and DU145 cells express higher mRNA and/or protein levels of
numerous IAPs, as compared to the LNCaP cell line, which may
well be associated with the observed differences in resistance to
apoptosis, even after p53 functional restoration [49].
As regards p27, it is noteworthy that this key player in cell cycle
regulation has shown only minimal effects in the presence of
cadmium. Reduced cellular levels of p27, mostly due to
deregulation of the post-translational processing of the protein,
have been associated to malignant progression [50]. In particular,
low levels or loss of p27 have been shown to correlate with more
aggressive phenotype and poor survival in prostate cancer [51,52].
Nevertheless, clearly detectable amounts of p27 (often relatively
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the prostate cell lines used here, even if it can not be excluded that
one or more of them express mutated p27. The general lack of a
significant increase of this protein after cadmium treatment at
concentrations ,30 mM suggests, rather, that cadmium at low
doses is not able to induce p27 up-regulation and the consequent
p27-mediated growth inhibition in these prostate cell lines.
Instead, in cadmium-responsive cells (more specifically RWPE-1,
LNCaP, CTPE and, to a minor extent, 22Rv1 cells), the effects of
low-dose cadmium on cell survival, apoptosis-induction and cell
cycle regulation seem to be mostly mediated by the activation of
p53 and its downstream target p21 (with the possible exception, for
this latter, of LNCaP cells).
In conclusion, the results presented here have revealed that
cadmium has the ability to induce p53-dependent apoptotic cell
death in human prostate epithelial cells. As demonstrated by our
comparative analysis, wild type p53-expressing cell lines are more
sensitive to cadmium treatment than cells harboring mutated p53
alleles, while apoptosis induction and inhibition of cell prolifera-
tion positively correlate with accumulation of functional p53
protein and overexpression of the cell cycle inhibitor p21, a well
characterized p53 target (except in the case of LNCaP cells,
apparently exhibiting a peculiar inverse relationship between p53
and p21 expression). We have further assessed this p53
dependence in a more direct manner, by using a p53 siRNA
strategy to prevent accumulation of p53 protein in RWPE-1 and
LNCaP cells following cadmium chloride exposure. Conversely,
adenoviral p53 gene transfer was not sufficient to ‘‘restore’’
cadmium sensitivity in PC-3 and DU145 cells, which are not able
to express functional p53 protein. This last finding implies that
PC-3 and DU145 resistance to cadmium may depend not only on
the absence of wild type p53 gene, but also on some other
mechanism(s) like, for instance, the overexpression of IAPs.
Together, our results identify p53 as a major player in
cadmium-induced apoptosis in the prostate. Furthermore, by
showing that prostate cells carrying mutated p53 alleles are able to
escape from apoptosis induction, they suggest a possible selection
mechanism operating in prostate cell populations exposed to
cadmium toxic action, through which p53-mutated cells, that are
more prone to give rise to tumor formation, may survive and
become predominant, while wt p53 cells are progressively
removed by apoptosis. Since the acquisition of apoptotic resistance
may be crucial in cadmium-induced malignant transformation, as
already evidenced in cadmium-adapted cells displaying a signif-
icantly attenuated apoptotic response, further characterization of
the pathways involved and a thorough comparative proteome
analysis of the different prostate epithelial cells studied here,
treated or not with this heavy metal, would certainly improve our
understanding of cadmium carcinogenesis in the prostate.
Supporting Information
Table S1 Absence of micronucleus induction in differ-
ent prostate epithelial cell lines, after 2-day exposure to
3o r1 0mM CdCl2. The percentages of binucleated cells with
micronuclei are reported in the column evidenced in purple.
Examples of binucleated cells with micronuclei, one for each cell
line, are shown in the images on the right. * P,0.05, ** P,0.01.
(TIF)
Text S1 Evaluation of cadmium genotoxicity in prostate
epithelial cell lines by means of cytokinesis-block
micronucleus (CBMN) assay.
(DOC)
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